Breastfeeding While Taking Invanz (Ertapenem)
Yes, a breastfeeding mother can safely continue breastfeeding while taking Invanz (ertapenem), as the drug is present in breast milk at very low concentrations that are unlikely to harm the infant.
Evidence from FDA Drug Label
The FDA label for Invanz provides direct human data on ertapenem transfer into breast milk 1. In a study of 5 lactating women with pelvic infections receiving 1g IV ertapenem:
- Breast milk concentrations within 24 hours of the last dose ranged from <0.13 to 0.38 mcg/mL (very low levels)
- Peak concentrations were not even assessed because levels were so minimal
- By day 5 after stopping therapy, ertapenem was undetectable in 4 women and below quantitation limits in 1 woman
- The label states: "The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for INVANZ" 1
Supporting Guideline Evidence
The 2020 Association of Anaesthetists guideline on breastfeeding explicitly states that "short courses of antibiotics are commonly used peri-operatively. There is no evidence of harmful effects in breastfeeding women" 2. This guideline emphasizes that most antibiotics used in clinical practice are compatible with continued breastfeeding.
Additional Context on Carbapenem Safety
While the provided evidence specifically addresses ertapenem (Invanz), there is also data on meropenem, another carbapenem antibiotic. A case report showed meropenem concentrations in breast milk averaged 0.48 mcg/mL with maximum of 0.64 mcg/mL, resulting in calculated infant exposure of only 0.18% of the maternal dose, with no adverse effects noted in the breastfed infant 3. This supports the general safety profile of carbapenems during lactation.
Clinical Decision Framework
The mother should continue breastfeeding while on Invanz because:
- Ertapenem concentrations in breast milk are minimal (<0.38 mcg/mL)
- The amount transferred represents a negligible percentage of therapeutic pediatric doses
- No data exists showing adverse effects in breastfed infants
- The benefits of breastfeeding (nutrition, immunity, bonding) far outweigh the theoretical minimal risk
- Antibiotics as a class are generally compatible with breastfeeding 4, 5
Important Caveats
- Monitor the infant for potential (though unlikely) effects such as diarrhea, rash, or changes in feeding patterns
- The study data comes from transitional milk (5-14 days postpartum), which may not perfectly reflect mature milk concentrations, though this is unlikely to be clinically significant 1
- If the infant develops any concerning symptoms, contact a healthcare provider, but this should not automatically mean stopping breastfeeding
Note on Drug Name Confusion
The question mentions "meropenem (Invanz)" but Invanz is actually ertapenem, not meropenem. These are two different carbapenem antibiotics. The answer above addresses Invanz/ertapenem specifically, which is what the mother is actually taking based on the drug name.